Roche (SIX:RO) jumped about 4% after Phase III Krascendo-1 found KRAS G12C drug divarasib delivered superior survival versus approved rivals in NSCLC, while the company also unveiled the Axelios 1 next‑generation sequencing platform with a Summer 2026 research‑use rollout.
Previous Week Recap
- Roche Nabbed Superior KRAS G12C NSCLC Survival: Roche (RO) shares rose ~4% after Phase III Krascendo-1 showed KRAS G12C drug divarasib beat approved rivals in NSCLC, reporting superior survival in global head‑to‑head testing.
- Roche Debuts Axelios 1 Platform: Roche (RO) unveiled the Axelios 1 next‑generation sequencing platform with planned Summer 2026 research‑use commercial rollout in select markets; shares moved modestly after the announcement.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.